Stem cell transplantation for rheumatic autoimmune diseases

Area of Science:

• Immunology
• Transplantation Medicine
• Rheumatology

Background:

• Immunoablative therapy and hematopoietic stem cell transplantation (HSCT) offer a potential "reset" for immune system dysregulation in autoimmune conditions.
• HSCT involves reinfusing hematopoietic stem cells, either autologous (patient's own) or allogeneic (donor's), to establish a non-autoimmune immune system.

Purpose of the Study:

• To review the efficacy and safety of HSCT in refractory autoimmune diseases.
• To highlight the immunological changes induced by HSCT and their impact on disease activity.
• To discuss the current status and future directions of HSCT research in autoimmune conditions.

Main Methods:

• Analysis of retrospective cohort studies, case series, and translational research involving HSCT for autoimmune diseases.
• Evaluation of immune system alterations, including changes in B cells, T cells, monocytes, NK cells, and dendritic cells.
• Assessment of clinical outcomes, disease activity, treatment-related morbidity, and mortality.

Main Results:

• HSCT induces significant immune system alterations, including elimination of autoantibody-producing plasma cells and induction of regulatory T cells.
• Marked and long-term improvements in disease activity are observed in conditions such as systemic sclerosis, systemic lupus erythematosus, and juvenile idiopathic arthritis.
• Treatment-related mortality has decreased to approximately 7% due to improved patient selection and transplant protocols.

Conclusions:

• HSCT is an effective intensive treatment for refractory autoimmune diseases, leading to profound immune modulation and sustained clinical benefits.
• Ongoing prospective, randomized, controlled trials are crucial to further validate HSCT efficacy and expand its application to other conditions.
• Continued research and refinement of transplant regimens are essential to optimize outcomes and minimize risks associated with HSCT.